Samsung Bioepis has appointed Kyung-Ah Kim as president and CEO, succeeding Christopher Hansung Ko. The leadership change ...

US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced ...

Japanese drugmaker Otsuka has announced the submission of a New Drug Application (NDA) to the Japanese Ministry of Health, ...

Berlin, Germany-based Eckert & Ziegler Radiopharma has received approval of its proprietary non-carrier added Lutetium-177 ...

PTC Therapeutics' Phase II trial for utreloxastat in ALS failed to meet its primary endpoint, showing no significant ...

Swiss drugmaker Idorsia was trading more than 10% higher by lunchtime on Wednesday. Idorsia earlier announced that it has entered into exclusive negotiations with an undisclosed party for the global ...

The International Federation of Manufacturers and Associations (IFPMA) today announced that Dr Thomas Schinecker, chief ...

Clinical-stage US CAR-T therapies developer Poseida Therapeutics saw its shares skyrocket 227% to $9.36 pre-market today, on ...

The Californian company earlier announced positive data at 52 weeks in a double-blind, dose-ranging Phase II study with ...

BRL Medicine raised $27 million in a Series B+ round, led by CSPC Fund, to advance its gene and cell therapies for genetic ...

Italian oncology focused biotech Nerviano Medical Sciences yesterday announced that it has successfully negotiated with ...

Roche’s Phase III SKYSCRAPER-01 trial missed its primary endpoint, with tiragolumab combined with Tecentriq failing to ...